PureTech, Seaport Advance GlyphAllo in Depression Therapy
BOSTON, Massachusetts, March 26, 2026 PureTech Health has announced that its founded entity, Seaport Therapeutics, has published first-in-human clinical...
Major Depressive Disorder
Advertisement
Shionogi Launches ZURZUVAE for Major Depression in Japan
OSAKA, Japan, March 19, 2026 Shionogi & Co., Ltd. has officially announced the commercial launch of ZURZUVAE® (zuranolone) 30...
Tonix Wins FDA IND Clearance to Launch Phase 2 Depression Trial
Chatham, N.J. — Nov. 24, 2025 — Tonix Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has...
FDA Clears Tonix IND for TNX-102 SL in Major Depression
Chatham, New Jersey, November 24, 2025 — Tonix Pharmaceuticals announced that the U.S. Food & Drug Administration has cleared...
FDA Clears CAPLYTA® as New Adjunctive Therapy for Depression
Titusville, New Jersey – November 6, 2025 – Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and...
Advertisement
